Yumanity Therapeutics Valuation
Is YMTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for YMTX?
Other financial metrics that can be useful for relative valuation.
|What is YMTX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does YMTX's PS Ratio compare to its peers?
|YMTX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
ONVO Organovo Holdings
VYNT Vyant Bio
ABEO Abeona Therapeutics
YMTX Yumanity Therapeutics
Price-To-Sales vs Peers: YMTX is good value based on its Price-To-Sales Ratio (3.5x) compared to the peer average (8.9x).
Price to Earnings Ratio vs Industry
How does YMTX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: YMTX is good value based on its Price-To-Sales Ratio (3.5x) compared to the US Biotechs industry average (13.8x)
Price to Sales Ratio vs Fair Ratio
What is YMTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||3.5x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate YMTX's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of YMTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate YMTX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate YMTX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.